Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
HeartSciences Inc. - Warrant
(NQ:
HSCSW
)
0.0717
-0.0001 (-0.14%)
Streaming Delayed Price
Updated: 9:44 AM EDT, Oct 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
101
Open
0.0717
Bid (Size)
0.0700 (3)
Ask (Size)
0.0717 (10)
Prev. Close
0.0718
Today's Range
0.0717 - 0.0717
52wk Range
0.0301 - 0.2000
Shares Outstanding
10,362,284
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
September 11, 2025
From
HeartSciences Inc.
Via
GlobeNewswire
HeartSciences Announces Conference Participation and Investor Webinar
August 15, 2025
Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85
From
HeartSciences Inc.
Via
GlobeNewswire
Performance
YTD
+43.7%
+43.7%
1 Month
-45.1%
-45.1%
3 Month
-36.9%
-36.9%
6 Month
+46.0%
+46.0%
1 Year
+112.1%
+112.1%
More News
Read More
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
July 24, 2025
From
HeartSciences Inc.
Via
GlobeNewswire
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
June 04, 2025
From
HeartSciences Inc.
Via
GlobeNewswire
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
June 03, 2025
From
HeartSciences Inc.
Via
GlobeNewswire
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
May 29, 2025
From
HeartSciences Inc.
Via
GlobeNewswire
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
May 20, 2025
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
May 08, 2025
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
May 07, 2025
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
May 01, 2025
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
March 13, 2025
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
March 10, 2025
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
December 16, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
November 13, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
October 14, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
September 12, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
September 12, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
July 29, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
July 26, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
July 25, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
July 11, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Regains Compliance with Nasdaq Listing Requirements
June 04, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
May 20, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
April 24, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences to Present at the LD Micro Invitational XIV Conference
April 02, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is HeartSciences Inc. - Warrant publicly traded?
Yes, HeartSciences Inc. - Warrant is publicly traded.
What exchange does HeartSciences Inc. - Warrant trade on?
HeartSciences Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for HeartSciences Inc. - Warrant?
The ticker symbol for HeartSciences Inc. - Warrant is HSCSW on the Nasdaq Stock Market
What is the current price of HeartSciences Inc. - Warrant?
The current price of HeartSciences Inc. - Warrant is 0.0717
When was HeartSciences Inc. - Warrant last traded?
The last trade of HeartSciences Inc. - Warrant was at 10/29/25 09:44 AM ET
What is the market capitalization of HeartSciences Inc. - Warrant?
The market capitalization of HeartSciences Inc. - Warrant is 742.98K
How many shares of HeartSciences Inc. - Warrant are outstanding?
HeartSciences Inc. - Warrant has 743K shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.